EMEA-001539-PIP01-13-M05
Table of contents
Key facts
| Invented name |
Lokelma
|
| Active substance |
sodium zirconium cyclosilicate
|
| Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
| Decision number |
P/0477/2021
|
| PIP number |
EMEA-001539-PIP01-13-M05
|
| Pharmaceutical form(s) |
Powder for oral suspension
|
| Condition(s) / indication(s) |
Treatment of hyperkalaemia
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|